Kintor
Kintor
Kintor

About Us

We focus on dermatology and oncology with substantial unmet medical needs,especially androgen receptor-related diseases,

including alopecia, acne, prostate cancer, liver cancer and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

Picture Name

Small-molecule drugs

Kintor Pharma focuses on dermatology and oncology. Our expanded pipeline now includes AR degraders, AR-PROTAC, mTOR inhibitor, Hedgehog inhibitor, and cMyc inhibitor.

Innovative biologics

Kintor Pharma's first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers. 

Combination therapies

To provide the best treatment for prostate and liver cancers and other diseases, Kintor Pharma is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

Picture Name

R&D Platform

Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a……

Picture Name
Picture Name

Manufacturing base

 Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing bas……

Picture Name
Picture Name

Business operation

 In anticipation of the commercial launch of our products, Kintor……

Picture Name

News Center

2025-08-12

Phase II Clinical Trial Of GT20029 Gel For The Treatment Of Acne In China Reached Primary Endpoint

Suzhou, 12 August, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Phase II Clinical Trial of its in-house developed androgen receptor (AR) proteolysis targeting chimera (PROTAC) compound GT20029 for the treatment of acne has read out the topline results. Results indicated that the Phase II Clinical Trial has successfully met the primary study endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy, safety and pharmacokinetics.
Picture Name

2025-07-31

Completion Of Patient Enrollment In Phase III Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult AGA In China

Suzhou, 31 July, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the enrollment of 666 patients has been completed for the Phase III Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA. The Pivotal Clinical Trial adopts a phase II/III operational seamless design, and the phase II stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety.
Picture Name

2025-07-24

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult AGA In China Reached Primary Endpoint

Suzhou, 24 July, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety.
Picture Name
View more
Picture Name

Work at Kintor

We're developing new products to improve human health,and we're looking for people like you to help shape the future at Kintor Pharmaceuticals.We're building a company based on curiosity, talent, and intellectual capital. We provide employees with opportunities for career development and personal growth.lf you're interested  in joining our team, please send your CV to kintor- HR@kintor. com. cn.

Join Us

Kintor